

Current Report No 9

Patent protection has been granted for a set of primers for amplifying the nucleotide sequence of *Borrelia burgdorferi*, a method for detecting *Borrelia burgdorferi*, a method for diagnosing Lyme disease and a kit for diagnosing Lyme disease.

The Executive Board of Genomtec S.A. („Company”, „Issuer”) registered in Wrocław, Poland, hereby reports that today the Company obtained patent document issued by the Polish Patent Office on 23 March 2021. The title of the Patent is "Primers for amplifying the nucleotide sequence of *Borrelia burgdorferi*, a method for detecting *Borrelia burgdorferi*, a method for diagnosing Lyme disease and a kit for diagnosing Lyme disease ".

The most common zoonosis (disease or infection which is likely to be naturally transmitted from animals to man) in Poland is Lyme disease caused by spirochetes of the genus *Borrelia burgdorferi*. Non-specific systemic symptoms and varied clinical presentation as well as problems in laboratory diagnostics often cause difficulties in the diagnosis of Lyme disease. In clinical practice, it is important to detect an early stage of the disease, which is possible thanks to the Issuer's invention.

The Issuer informs that this is the second patent granted by the Patent Office of the Republic of Poland and the third patent received by the Company. The Issuer has pending twenty patent applications all over the world. The Issuer's Management Board decided that the receipt of the above patent is confidential information, as in the case of an entity operating on the molecular diagnostics market, it is necessary to effectively protect intellectual property and designs. Properly secured intellectual property and designs may constitute the Issuer's competitive advantage, allowing safer commercialization under condition that full protection is ensured on selected markets.

In the opinion of the Management Board, a high degree of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial contracts with selected partners in the scope of implementing the commercialization strategy.

Patent proceedings are aimed at securing key interests and are in line with the Issuer's development strategy, which includes building a portfolio of intellectual property rights. Diagnostics of bacterial infections, including Lyme infections, is one of the key areas of technology developed by the Issuer. For these reasons, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.